Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

Designerly's Cooper Adwin looks at why generative AI Is re-engineering skin rejuvenation and phasing out animal collagen.